source
- Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 pushSobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.
- India tightens penalties for submitting false regulatory documentsThe Indian government has introduced stricter penalties for applicants who submit misleading, fake, or fabricated documents to regulatory authorities, prohibiting them from making further filing re…